NASDAQ:KALV KalVista Pharmaceuticals Q1 2026 Earnings Report $15.61 -0.35 (-2.19%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$15.73 +0.12 (+0.77%) As of 09/9/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast KalVista Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.91Beat/MissN/AOne Year Ago EPSN/AKalVista Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.97 millionBeat/MissN/AYoY Revenue GrowthN/AKalVista Pharmaceuticals Announcement DetailsQuarterQ1 2026Date9/11/2025TimeBefore Market OpensConference Call DateThursday, September 11, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile KalVista Pharmaceuticals Earnings HeadlinesKalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7 at 11:01 PM | seekingalpha.comKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | finanznachrichten.deThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025September 4, 2025 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comKalVista Pharmaceuticals Stock Sees RS Rating Rise To 82August 28, 2025 | msn.comSee More KalVista Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like KalVista Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your email. Email Address About KalVista PharmaceuticalsKalVista Pharmaceuticals (NASDAQ:KALV) is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions. The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema. These candidates are designed to address unmet needs in rare disease and ophthalmology by improving patient convenience, reducing the burden of disease manifestations and potentially offering long‐lasting therapeutic benefit. Founded in 2010 and headquartered in Cambridge, England, KalVista also maintains operations in Boston, Massachusetts. The company completed its initial public offering on the Nasdaq exchange in 2015 and has since advanced its pipeline through a combination of in‐house research, strategic collaborations and contract manufacturing partnerships. KalVista’s programs target patient populations in North America, Europe and other markets with significant unmet medical need. KalVista is led by President and Chief Executive Officer Anna Berkenstock, PhD, who brings extensive experience in drug discovery, development and corporate strategy. The broader leadership team and board of directors draw on deep expertise in rare disease biology, protease chemistry and clinical development to guide the company’s strategic priorities and global growth.Written by Jeffrey Neal JohnsonView KalVista Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
